Belize vs Niue: Statin use vs. average non-HDL cholesterol levels

Belize
3.4
in 2018
Niue
3.4
in 2018
Belize rank
75th
Niue rank
75th

Statin use vs. average non-HDL cholesterol levels over time

  • Belize
  • Niue
01234198019992018

How they compare

Belize currently reports 3.4 against 3.4 in Niue, a difference of 0.

The two have swapped places 1 time across 39 shared years of data; in 1980 it was Belize ahead.

Belize ranks 75th and Niue ranks 75th of 191 countries.

Niue has averaged higher in every one of the 4 decades both report.

Head to head by decade

Decade Belize Niue Difference Ahead
1980s 3.37 3.37 0 Niue
1990s 3.29 3.5 0.21 Niue
2000s 3.27 3.45 0.18 Niue
2010s 3.37 3.4 0.0333 Niue

Averages of every year both report within each decade.

Frequently asked questions

Which has higher statin use vs. average non-hdl cholesterol levels, Belize or Niue?
Belize, at 3.4 against 3.4 in Niue as of 2018.
What is the difference in statin use vs. average non-hdl cholesterol levels between Belize and Niue?
0, with Belize ahead.
How many years of comparable data are there for Belize and Niue?
39 years are reported by both, from 1980 to 2018.
How do Belize and Niue rank globally for statin use vs. average non-hdl cholesterol levels?
Belize ranks 75th and Niue ranks 75th of 191 countries.
Where does this data come from?
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.